Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Provigil (Modafinil) – EU announces anti-trust probe into a Cephalon – Teva deal concerning generic Provigil (The IP Factor) (GenericsWeb)

Court of Appeals for District of Columbia lifts injunction on federal funding of embryonic stem-cell research: Sherley et al v Kathleen Sebelius et al (Patent Baristas) (Ars Technica) (SCOTUSblog)

India: PM instructs negotiators – no TRIPS plus IP obligation in EU FTA (Generic Pharmaceuticals and IP)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

WHO calls for proposals to finance R&D for diseases affecting developing world (IP Watch)

EU: Scientists oppose European stem cell patent ban (PatentlyBIOtech)

India: PM instructs negotiators – no TRIPS plus IP obligation in EU FTA (Generic Pharmaceuticals and IP)

US: Court of Appeals for District of Columbia lifts injunction on federal funding of embryonic stem-cell research: Sherley et al v Kathleen Sebelius et al (Patent Baristas) (Ars Technica) (SCOTUSblog)

US: Academics criticize the MMA’s failure-to-market forfeiture provisions as an anemic mechanism for parked exclusivity and the MMA’s DJ provisions as a paper tiger (FDA Law Blog)

US: Blockbuster drugs that will go generic soon (GenericsWeb)

US: Implementing the Biologics Price Competition and Innovation Act? (Patent Law Practice Center)

US: Abraxis files for patent term adjustment calculation review for patent entitled ‘Compositions and methods of delivery of pharmacological agents’ (Patent Docs)

US: ITC: Target date set in Certain Vaginal Ring Birth Control Devices (ITC 337 Law Blog)

US: Court confused by patent reexamination results: Cellectricon v Fluxion Biosciences (Patents Post-Grant)

Products

AndroGel (Testosterone) – US: Abbott sues Teva in attempt to block US sales of generic AndroGel until patent expiry in 2021 (GenericsWeb)

Benlysta (Belimumab) – US: Human Genome Sciences file for declaratory judgment of invalidity, unenforceability and non-infringement against Genentech (Patent Docs)

Cymbalta (Duloxetine) – US: District Court S D Indiana blocks generic Duloxetine sales for term of compound patent: Eli Lilly and Co v Wockhardt (GenericsWeb) (IPBiz)

Focalin (Dexmethylphenidate) – US: Celgene, Novartis file patent infringement suit Actavis following Para IV challenge (Patent Docs)

Humira (Adalimumab) – US: Abbott files for declaratory judgment of patent invalidity against Mathilda and Terence Kennedy Institute (Patent Docs)

Latisse (Bimatoprost) – US: Allergan, Duke University file patent infringement complaint against Sandoz in response to Para IV certification (Patent Docs)

Lipitor (Atorvastatin) – US: District Court dismisses Mylan’s complaint against FDA concerning generic Lipitor (Orange Book Blog)

Neurontin (Gabapentin) – US: District Court New Jersey: $3.8 billion reasonable royalty opinion is not inadmissible despite similarity to $3.8 billion lost profits opinion where hypothetical negotiations: Warner-Lambert Company, et. al. v. Purepac Pharmaceutical, et. al. (Docket Report)

Provigil (Modafinil) – EU announces anti-trust probe into a Cephalon – Teva deal concerning generic Provigil (The IP Factor) (GenericsWeb)

Valsartan – Norway: District Court of Oslo forbids Actavis to market any products containing Valsartan produced by using the process QSSA Route C until 13 May 2011 (EPLAW)

Welchol (Colesevelam) – US: Daiichi Sankyo, Genzyme file patent infringement complaint against Watson in response to Para IV certification filing (Patent Docs)